ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Uric acid-associated psychopathology in first-episode drug-naïve schizophrenia stratified by depressive symptoms.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Schizophrenia patients with depressive symptoms may represent a distinct clinical subtype with unique metabolic features. This study investigated divergent metabolic-psychopathological patterns in first-episode drug-naïve schizophrenia (FEDN-SCZ) patients stratified by depressive symptoms. We recruited 289 FEDN-SCZ patients and 128 healthy controls. Psychopathological symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and depressive symptoms were evaluated with the 24-item Hamilton Depression Rating Scale (HAMD-24). Patients were stratified into subgroups based on HAMD-24 cut-off scores. Metabolic parameters, including uric acid (UA), fasting glucose, glycated hemoglobin (HbA1c), fasting insulin, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol, were systematically measured. FEDN-SCZ patients exhibited marginally higher UA levels than healthy controls (p = 0.050), with elevated levels observed in patients with depressive symptoms compared to those without (351.41 vs. 317.64 µmol/L, p = 0.047). The UA-PANSS association was moderated by depressive status (significant interactions for negative, general, and total PANSS scores, all p < 0.05), with simple slopes significant only in the depression group. Multiple regression analyses revealed subgroup-specific predictors: in the depressive subgroup, higher UA was associated with greater symptom severity, while HDL-C showed a protective effect; in non-depressive patients, glycemic indices (HbA1c and glucose) emerged as significant predictors (p < 0.05). The UA-psychopathology association was exclusive to FEDN-SCZ patients with depressive symptoms, while non-depression patients were characterized by glucose and energy dysregulation. These findings underscore the importance of stratified management strategies addressing both psychiatric and metabolic health.
Indexed as
Identifiers
42859188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.